You are here

Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX

Last updated on June 7, 2019

FOR MORE INFORMATION
Study Location
Pfizer
New York, New York, 10017 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Rheumatoid Arthritis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- At least one claim for tofacitinib between 01 January 2014 and 31 January 2017 (the
identification period).

- Presence of The International Classification of Diseases, 9th Revision, Clinical
Modification (ICD-9 CM) code for RA (in any position) during the one-year pre-index
period or on the index date. ICD-9 = 714.0x-714.4x & 714.81 or ICD10 = M05.* &
M06.0*-M06.3* or M06.8*-M06.9*.

- At least 18 years old as of the index date.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patients with claims for other conditions for which biologics are used during the
one-year pre-index period or on the index date: ankylosing spondylitis, Crohn's
disease, psoriasis, psoriatic arthritis, or ulcerative colitis will be excluded from
the study.

- Patients with evidence of the index medication during the one-year pre-index period
will be removed from the analysis. Patients will be allowed to have been treated with
other biologics approved for RA (Tumor-Necrosis Factor-alpha inhibitors (TNFi)
[adalimumab (Humira), etanercept (Enbrel), certolizumab pegol (Cimzia), golimumab
(Simponi), infliximab (Remicade)] and non-TNFi's with alternative mechanisms of action
[abatacept (Orencia), and rituximab (Rituxan), anakinra (Kineret), tocilizumab
(Actemra)]) during the one-year pre-index period.

NCT03975790
Pfizer
Completed
Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Rheumatoid Arthritis
NCT03981900
All Genders
18+
Years
Multiple Sites
Crohn Desease, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
NCT02925338
All Genders
6+
Years
Multiple Sites
Systemic Lupus Erythematosus, Rheumatoid Arthritis
NCT03334851
All Genders
18+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now